Pretreatment SUV(max) value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy

OBJECTIVE: Stage III disease accounts for approximately one-fourth of all non-metastatic non-small cell lung cancer (NSCLC). The patients who are not candidates for curative resection are offered concomitant chemoradiotherapy. In this subgroup, which is difficult to manage, studies that address the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaprak, Gokhan, Ozcelik, Melike, Gemici, Cengiz, Seseogullari, Ozgur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593921/
https://www.ncbi.nlm.nih.gov/pubmed/31297478
http://dx.doi.org/10.14744/nci.2019.02212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593921/
https://www.ncbi.nlm.nih.gov/pubmed/31297478
http://dx.doi.org/10.14744/nci.2019.02212

Ejemplares similares